Sugi Predict

Sugi Predict / Compounds / SCHEMBL1490647

SCHEMBL1490647

SCHEMBL1490647

CC(C)Cn1c(CO)nc2c(N)nc3c(c21)CCCC3

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 11/20 0.38
▸ TLR8 Q9NR97 2/20 0.37
▸ CHRNE Q04844 1/20 0.34
▸ ACHE P22303 2/20 0.32
▸ KDM4E B2RXH2 3/20 0.31
▸ EEF2K O00418 1/20 0.31
▸ HPGD P15428 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ BPTF Q12830 1/20 0.31
▸ NOS3 P29474 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ NOS2 P35228 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ CASP1 P29466 1/20 0.30
▸ MAPK10 P53779 1/20 0.30
▸ CASP7 P55210 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8113805 0.89 TLR7 (0.39) TLR7TLR8ACHEKDM4EHPGD
SCHEMBL5124071 0.89 TLR7 (0.36) TLR7TLR8ACHEKDM4EHPGD
SCHEMBL8113959 0.89 TLR7 (0.45) TLR7TLR8ACHEKDM4EEEF2K
SCHEMBL9047383 0.88 MEN1 (0.38) TLR7TLR8KDM4EHPGDMEN1
Hydrochloric Acid SCHEMBL1490823 0.86 TLR7 (0.38) TLR7TLR8ACHEKDM4EHPGD
SCHEMBL8115012 0.85 TLR7 (0.41) TLR7TLR8ACHEKDM4EHPGD
SCHEMBL1490830 0.85 TLR7 (0.41) TLR7TLR8ACHEKDM4EHPGD
SCHEMBL5448652 0.84 TLR7 (0.33) TLR7TLR8
SCHEMBL5118920 0.83 TLR7 (0.42) TLR7TLR8
SCHEMBL8122097 0.83 KDM4E (0.36) TLR7ACHEKDM4EHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199538-A1 Pharmaceutical formulation comprising an immune response modifier 3M INNOVATIVE PROPERTIES COMPANY 2003-10-23 — — US claimed
EP-0708773-B1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING & MFG (US) 2000-10-04 — — EP claimed
US-5352784-A Viricides; immunomodulators MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-10-04 — — US claimed
US-8598192-B2 Hydroxylamine substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-12-03 — — US disclosed
EP-1651190-B1 FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER 3M INNOVATIVE PROPERTIES CO (US) 2012-09-19 — — EP disclosed
US-7968562-B2 an immune response modifier (IRM) compound 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine; fatty acids such as oleic acid, isostearic acid; hydrophobic, aprotic caprylic/capric triglyceride miscible with fatty acid; actinic keratosis, postsurgical scars, warts, atopic dermatitis 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-06-28 — — US disclosed
US-7897767-B2 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 — — US disclosed
EP-1682544-A4 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2009-05-06 — — EP disclosed
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-04-23 — — US disclosed
EP-1450804-B9 PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER 3M INNOVATIVE PROPERTIES CO (US) 2009-04-01 — — EP disclosed
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. 2009-02-12 — — US disclosed
WO-2005123079-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-12-29 — — WO disclosed
WO-2005048933-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 — — WO disclosed
WO-2005048945-A2 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 — — WO disclosed
EP-0708773-B1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING & MFG (US) 2000-10-04 — — EP disclosed
US-5886006-A VIRICIDES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-03-23 — — US disclosed
US-5648516-A INTERFERON BIOSYNTHESIS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-07-15 — — US disclosed
US-5627281-A CHEMCAL INTERMEDIATES FOR VIRICIDES BY INDUCING SYNTHESIS OF INTERFERONS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-05-06 — — US disclosed
US-5444065-A Viricides MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-08-22 — — US disclosed
US-5352784-A Viricides; immunomodulators MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199538-A1 Pharmaceutical formulation comprising an immune response modifier ICOS, STAT6, INMT TLR7 35/4885TLR8 40/4885CHRNE 2254/4885
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES IL2, IL4, IFNG TLR7 54/4885TLR8 140/4885CHRNE 2555/4885
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES IFNG, IL2, IRF3 TLR7 33/4885TLR8 88/4885CHRNE 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.